Human Studies
SMS cells are being evaluated in human studies to assess their potential in treating diseases such as:
Respiratory diseases:
COPD
Bio-manufactured SMS cells are administered via nebulization, enabling direct delivery to the lungs. Their unique size and resilience characteristics make this method of cell delivery feasible and effective. A phase 1 clinical trial is currently enrolling 18 patients with mild to moderate COPD, organized into three ascending-dose cohorts.
The primary endpoint is safety and tolerability, while secondary and exploratory endpoints include early signs of efficacy, such as improvements in lung function, reduction in exacerbation frequency, and enhanced patient-reported outcomes.
Unlocking Cartilage Repair with SMS Cells
Chondrocyte Regeneration
SMS cells have been tested for their effect on chondrocytes—the key cells responsible for producing and maintaining joint cartilage.
Binding of SMS cells to chondrocytes triggers changes in the expression of thousands of genes, with the overall pattern strongly supporting cartilage repair.
